Last reviewed · How we verify
NCT05967871
Pilot Feasibility Study of Fecal Microbiota Transplant for the Treatment of Small Intestinal Bacterial Overgrowth
Phase 1 trial testing Fecal Microbiota Transplant in Small Intestinal Bacterial Overgrowth in 20 participants. Currently enrolling.
31 December 2026
Quick facts
| Lead sponsor | McMaster Children's Hospital |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 11 March 2024 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 2 locations across Canada |
Drugs / interventions tested
- Fecal Microbiota Transplant — full drug profile →
Conditions studied
- Small Intestinal Bacterial Overgrowth — all drugs for Small Intestinal Bacterial Overgrowth →
Sponsor
McMaster Children's Hospital
Who can join
Adults 3 to 18, any sex, with Small Intestinal Bacterial Overgrowth. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of the study is to assess feasibility, and clinical efficacy of a novel Fecal Microbiota Transplantation protocol for the treatment of pediatric small intestinal bacterial overgrowth (SIBO).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05967871
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Fecal Microbiota Transplant
Trials testing the same drug.
- NCT05229289 — Efficacy and Safety of Fecal Microbiota Transplant for Secondary Prophylaxis of Hepatic Encephalopathy · NA · unknown
- NCT04139577 — FMT In High-Risk Acute GVHD After ALLO HCT · Phase 1 · completed
- NCT03363022 — To Assess the Role of Fecal Microbiota Transplant in Acute Liver Failure · NA · withdrawn
- NCT03998423 — Oral Fecal Microbiota Transplant Feasibility Study in Alzheimer's Disease · Phase 1 · terminated
- NCT04056026 — A Single Dose FMT Infusion as an Adjunct to Keytruda for Metastatic Mesothelioma · EARLY_PHASE1 · completed
Other recruiting trials for Small Intestinal Bacterial Overgrowth
Currently open trials in the same condition.
- NCT06298409 — Evaluating the Effect Of Rifaximin on the Gut Microbiota and Metabolome in SIBO Using CapScan® · Phase 1 · recruiting
Other McMaster Children's Hospital trials
Trials by the same sponsor.
- NCT06552455 — Post-extubation Pressures in Preterm Neonates: A CER Study · not yet recruiting
- NCT05230485 — Optimal High CPAP Pressures in Preterm Neonates Post-extubation · NA · unknown
- NCT03378167 — PediCRaFT: Pediatric Crohn's Disease Fecal Transplant Trial · Phase 1 · completed
- NCT03512158 — Non-invasive Respiratory Support in Preterm Infants · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05967871 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by McMaster Children's Hospital
- Last refreshed: 21 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05967871.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing